Phase 1b Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatmentof Advanced Solid Tumors (MINOTAUR Study)
Sponsor: |
Repare Therapeutics |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT9701 |
U.S. Govt. ID: |
NCT05147350 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to test how safe RP-6306 and FOLFIRI are when given together at different doses and on different schedules, and test how well RP-6306 and FOLFIRI work together to shrink solid tumors in the body. This is the first time RP-6306 is being given with FOLFIRI to humans. Cancers include esophageal cancer and colon and rectal cancer.
Investigator
Ryan Moy, MD
Are you at least 18 years old? |
Yes |
No |
Have you been diagnosed with colon, esophageal, or GI cancer? |
Yes |
No |